Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centre For Immunology & Infection Limited is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This single active matter indicates a focused prosecution phase for the company's intellectual property. The firm is currently working to resolve this outstanding action to advance its application toward allowance.
The portfolio is reviewed by 1 distinct examiner and 1 distinct art unit. This one-to-one ratio between examiners and art units shows that the company's current work is concentrated within a specific technical department. Practitioners can expect a consistent examination environment, as there is no variation in the personnel or departmental standards currently being applied to the portfolio.
GRABER, JAMES J is the busiest examiner for this company. This examiner is responsible for the 1 busiest examiner pending office action. Since GRABER, JAMES J handles the only active matter, the outcome of the entire pending portfolio depends on the interaction with this single individual. The concentration of work under GRABER, JAMES J allows for a focus on this examiner's specific requirements and historical patterns.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRABER, JAMES J | 1 | 46.7% | +57.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18359916 | NON-INVASIVE METHOD FOR GENERATING HUMAN THREE-DIMENSIONAL AND TWO- DIMENSIONAL NASOPHARYNGEAL ORGANOIDS | GRABER, JAMES J | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18359916 | NON-INVASIVE METHOD FOR GENERATING HUMAN THREE-DIMENSIONAL AND TWO- DIMENSIONAL NASOPHARYNGEAL ORGANOIDS | GRABER, JAMES J | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18359916 | NON-INVASIVE METHOD FOR GENERATING HUMAN THREE-DIMENSIONAL AND TWO- DIMENSIONAL NASOPHARYNGEAL ORGANOIDS | GRABER, JAMES J | 1631 | §103§112 | Final Rejection | 4d overdue | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial